Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Pipeline Insight - Substance Dependence - Part II - Alcohol (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 19/12/2007
- Report Title: Pipeline Insight - Substance Dependence - Part II - Alcohol
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 93
Introduction
The continued uptake of existing brands and the launch of two opioid antagonists will cause the market to grow at a compound annual growth rate of 13.5% from 2006 to reach $304m across the seven major markets by 2016. The alcohol dependence market requires a paradigm shift away from the public perception that it is a behavioral disorder towards being regarded as a treatable medical condition.
Scope
Analysis of epidemiology, unmet needs and clinical trial design in alcohol dependence with insight from key opinion leaders Overview of the current alcohol dependence market. Analysis of patient potential, marketing factors, commercial attractiveness and clinical attractiveness of key late-stage pipeline drugs. Indication-specific forecasts of key drug key late-stage pipeline drugs revenues to 2016.
Highlights
The current alcohol dependence pipeline is small in comparison to other central nervous system markets. Opioid antagonists are the most prevalent drug class in late-stage development and include two reformulations of naltrexone. It is believed that the current alcohol dependence pipeline to be weak and lacking in innovation.
The efficacy of currently marketed pharmaceutical products is limited, thereby leaving market opportunity for new therapies. Furthermore, in view of the poor medication compliance rate in alcohol dependent patients, pipeline drugs that possess the potential to improve patient compliance can expect to receive a strong uptake.
Companies developing naltrexone depot drugs will experience difficulty distinguishing their products from Vivitrol (naltrexone once-monthly controlled-release, Alkermes/Cephalon) unless they price their drugs competitively and/or incorporate an injection device that produces less pain and fewer injection site reactions.
Reasons to Purchase
Understand unmet needs and opportunities in this market based on the comments of interviewed key opinion leaders. Benchmark key late-stage alcohol dependence compounds against the current market leader. Assess the seven major market total sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential.
Scope
Highlights
Reasons to Purchase
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
